サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：好酸球増多症候群治療薬の世界市場（2022年～2028年）
市場調査レポート
商品コード
1159179

好酸球増多症候群治療薬の世界市場（2022年～2028年）

Hypereosinophilic Syndrome Drug Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 130 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
好酸球増多症候群治療薬の世界市場（2022年～2028年）
出版日: 2022年09月20日
発行: Orion Market Research
ページ情報: 英文 130 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の好酸球増多症候群治療薬の市場規模は、予測期間中に5.7%の大幅な成長すると予想されています。好酸球増多症候群の有病率の増加、医療インフラの改善、薬剤パイプラインの増加やさまざまな研究開発の増加は、市場の成長を後押ししています。

当レポートでは、世界の好酸球増多症候群治療薬市場について調査分析し、市場概要、競合情勢、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc.
  • Kyowa Kirin Co. Ltd.
  • Novartis AG
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場セグメンテーション

  • 世界の好酸球増多症候群治療薬市場：タイプ別
    • ベンラリズマブ
    • ダサチニブ
    • デクスプラミペキソール二塩酸塩
    • メポリズマブ
    • その他
  • 世界の好酸球増多症候群治療薬市場：用途別
    • 病院
    • クリニック
    • その他

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋
  • 世界のその他の地域

第6章 企業プロファイル

  • AstraZeneca
  • Knopp Biosciences LLC
  • Stemline Therapeutics Inc.
図表

LIST OF TABLES

  • 1. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
  • 2. GLOBAL BENRALIZUMAB HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
  • 3. GLOBAL DASATINIB HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
  • 4. GLOBAL DEXPRAMIPEXOLE DIHYDROCHLORIDE HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
  • 5. GLOBAL MEPOLIZUMAB HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
  • 6. GLOBAL OTHERS HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
  • 7. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
  • 8. GLOBAL HOSPITAL TREATED HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
  • 9. GLOBAL CLINICALLY TREATED HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
  • 10. GLOBAL OTHERS TREATED HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
  • 11. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021 - 2028 ($ MILLION)
  • 12. NORTH AMERICAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
  • 13. NORTH AMERICAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
  • 14. NORTH AMERICAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
  • 15. EUROPEAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
  • 16. EUROPEAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
  • 17. EUROPEAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
  • 18. ASIA-PACIFIC HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
  • 19. ASIA-PACIFIC HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
  • 20. ASIA-PACIFIC HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
  • 21. REST OF THE WORLD HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
  • 22. REST OF THE WORLD HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
  • 23. REST OF THE WORLD HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET, 2021 - 2028($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET BY SEGMENT, 2021 - 2028($ MILLION)
  • 3. RECOVERY OF GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET, 2021-2027 (%)
  • 4. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL BENRALIZUMAB HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL DASATINIB HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL DEXPRAMIPEXOLE DIHYDROCHLORIDE HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL MEPOLIZUMAB HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL OTHERS HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 11. GLOBAL HOSPITAL TREATED HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL CLINICALLY TREATED HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL OTHERS TREATED HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. US GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 16. CANADA GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 17. UK GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 18. FRANCE GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 19. GERMANY GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 20. ITALY GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 21. SPAIN GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 22. REST OF EUROPE GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 23. INDIA GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 24. CHINA GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 25. JAPAN GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 26. REST OF ASIA-PACIFIC GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
  • 27. REST OF THE WORLD GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
目次
Product Code: OMR2026014

Global Hypereosinophilic Syndrome Drug Market Size, Share & Trends Analysis Report by Type (Benralizumab, Dasatinib, Dexpramipexole Dihydrochloride, Mepolizumab, Others), and by Application (Hospital, Clinics, Others) Forecast 2022-2028

The global hypereosinophilic syndrome drug market is anticipated to grow at a substantial CAGR during the forecast period. The global hypereosinophilic syndrome drug market is growing due to the increasing prevalence of hypereosinophilic syndrome globally. Additionally, the growing drug pipeline and various research and development along with improvement in healthcare infrastructure are boosting the market growth. However, the lack of knowledge in the developing countries and cost of the drugs are the restraining factor for the market to grow.

The global hypereosinophilic syndrome drug market is segmented based on the type, and application. Based on the type, the market is segmented into benralizumab, dasatinib, dexpramipexole dihydrochloride, mepolizumab, others. Based on the application, the market is sub-segmented into hospitals, clinics, and others. The above-mentioned segments can be customized as per the requirements. Amongst the type, the benralizumab hypereosinophilic syndrome drug market is anticipated to grow more in the forecasted period. Based on the application segment, the hospital treated hypereosinophilic syndrome drug market is anticipated to grow more in the projected forecast period.

Regionally the global hypereosinophilic syndrome drug market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to hold the major share and dominate the global hypereosinophilic syndrome drug market. This is due to high prevalence of autoimmune disorders and cancer patients in this region. The Asia-Pacific region will hold the fastest growing market share after North America due to the increasing awareness and developing healthcare infrastructure of this region.

The major companies serving the global hypereosinophilic syndrome drug market include Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Novartis AG, Kyowa Kirin Co. Ltd., and many more. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new drug launches for the advancement of the treatment, to stay competitive in the market. Recently, in February 2019, AstraZeneca got USFDA approval of Orphan Drug Designation to Fasenra, a type of benralizumab drug for the treatment of hypereosinophilic syndrome.

Research Methodology

The market study of the global hypereosinophilic syndrome drug market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalogue.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global hypereosinophilic syndrome drug market Research and Analysis by Type
  • Global hypereosinophilic syndrome drug market Research and Analysis by Application

The Report Covers:

  • Comprehensive Research Methodology of the global hypereosinophilic syndrome drug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global hypereosinophilic syndrome drug market.
  • Insights about market determinants that are stimulating the global hypereosinophilic syndrome drug market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on The Global Hypereosinophilic Syndrome Drug Market
  • Recovery Scenario of Global Hypereosinophilic Syndrome Drug Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Bristol-Myers Squibb Co.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. F. Hoffmann-La Roche Ltd.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. GlaxoSmithKline Plc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Kyowa Kirin Co. Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Novartis AG
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Hypereosinophilic Syndrome Drug Market by Type
    • 4.1.1. Benralizumab
    • 4.1.2. Dasatinib
    • 4.1.3. Dexpramipexole Dihydrochloride
    • 4.1.4. Mepolizumab
    • 4.1.5. Others
  • 4.2. Global Hypereosinophilic Syndrome Drug Market by Application
    • 4.2.1. Hospital
    • 4.2.2. Clinic
    • 4.2.3. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca
  • 6.2. Knopp Biosciences LLC
  • 6.3. Stemline Therapeutics Inc.